News

Theses · Events · Sentiments
Sentiments
24-10-31 6.60%

Merck & Co posted higher-than-expected third-quarter earnings on Thursday on strong sales of its blockbuster cancer treatment Keytruda, but the …

24-10-31 6.20%

Merck reported third-quarter revenue and adjusted earnings that topped expectations. The company saw strong sales from its top-selling cancer drug …

24-10-31 0.00%

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Third-Quarter 2024 Financial Results.

24-10-24 39.80%

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers.

24-10-09 -30.00%

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--New Data to be Presented at IDWeek 2024 Reinforce Merck's Broad and Diverse Vaccines and Infectious …

24-10-01 0.60%

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of …

24-10-01 0.00%

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31.